-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 18, Henlius announced that its innovative PD-1 inhibitor slulimumab combined with chemotherapy in the first-line treatment of patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) was launched in the Phase 3 clinical study ASTRUM-00 In a planned interim analysis, the dual primary endpoints of progression-free survival (PFS) and overall survival (OS) were met as assessed by the Independent Data Monitoring Committee (IDM.
Slulimumab (trade name: Hansezoid) is a recombinant humanized anti-PD-1 monoclonal antibody injecti.
For slulimumab, Henlius is conducting 9 clinical trials of combined tumor immunotherapy in the world, covering a wide range of indications such as lung cancer, esophageal cancer, head and neck squamous cell carcinoma and gastric cancer, and fully covering the first-line treatment of lung canc.
The ASTRUM-007 study, which has achieved dual primary endpoints, is a randomized, double-blind, multicenter, phase 3 clinical study, with Professor Huang Jing from Cancer Hospital, Chinese Academy of Medical Sciences as the principal investigator, aiming to compare slulimumab Efficacy and safety of or placebo combined with chemotherapy in first-line treatment of patients with locally advanced/metastatic esophageal squamous cell carcino.
Esophageal cancer is a very common malignant tumor in the wor.
